biostudies-literatureUnknown50(12)Carvelli J<h4>Objectives</h4>Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.<h4>Design</h4>FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study.<h4>Setting</h4>Twelve clinical sites in France (ICU and general hospitals).<h4>Patients</h4>Patients receiving greater than or equal to 5 L oxygen/min to maintain Sp o2 greater than 93% (World Health Organization scale ≥ 5). Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ventilation (NIV) in cohort 1; HFO, NIV, or invasive mechanical ventilation (IMV) in cohort 2; and IMV in cohort 3.<h4>Interventions</h4>Patients were randomly assigned, in a 1:1 ratio, to receive avdoralimab or placebo. Critical care medicine1788-1798https://www.ebi.ac.uk/biostudies/studies/S-EPMC9674430biostudies-literatureAvdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).PMC9674430Tilmont ADemiselle JJacquier SDubief ELe Gac SMarrane GDhorne JBichon ABenarous LMourissoux GLanglade CNseir SChalal LDubois GLelievre JDLe Tohic SChirio DDeguenel-Nguyen AEbbo MCoutard BVindrios WBlondelon AClouzeau BSchleinitz NMonier ABourenne JBretagnol AMathonnet AKramer LLacombe KCauchois EVivier EFares JCamou FVely FViotti JJandeaux LMCarles MChauvel OBourhis MBezirganyan KJamet CPiperoglou CCoularet CGuisset ODelaune JBui HNBouzana FPerreau PAsselate BAmichi KDucours MBarthelemi LSebire MBrice SCarvelli JSpadoni SMerdji HIssa NFleurot OBourgoin NClerc ADemonchy EDe Nailly DLDesclaux AJulia ZDeluca BTran CPedenon-Peyrichout DMelica GLamarque JLe Grand JVeit VLarosa ASanz CBarbar SDBoyer-Chammard ACohen ASimeone PBreaud SGainnier MPinglis CMai-Anh NBollens DKamel TGallien SThiemele ACourjon JPastorino BBuscot MKarakunnel JHelms JMuller LBachelard ANatella PATellec SBlasco VElotmani LCua EInal IServant VChouaki-Benmansour NOualit LGhezzoul BLehingue SMeziani FVelly LMadjarian CPlantefeve GBarbier FBoughdiri NThiebaut LProvitolo VBoyer ABenzekri DDellamonica JDa Conceicao OMalvy DFraisse MRigault MCDelcoutre CRotolo FAllam HFOR COVID Elimination (FORCE) Study GroupBatista LMuller GRognon AMeyrieux SLescure XAmbert APedeboscq SLe Saux AGazoppi LPapazian LCotellon CBouskila NGarrido-Pradalie ESavini HDurieux FMalkoun RRunge IValera SDjabarouti SLe Dault EBrunet JCordier PYGuervilly CAouadenne-Mesbah AColombini NIsernia VMariller LTouitou IHutt-Clauss AAllardet-Servent JVillaroel MSDemaria OSalas VJean EBenrezzak NLetaillandier CPoissy JBruder NSaccheri CStuder AJavelle EKabala ADavide Barbar SRisso KLe Garlantezec PDesgrouas MPoulet AForel JMLloret SfalseAvdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).<h4>Objectives</h4>Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.<h4>Design</h4>FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study.<h4>Setting</h4>Twelve clinical sites in France (ICU and general hospitals).<h4>Patients</h4>Patients receiving greater than or equal to 5 L oxygen/min to maintain Sp o2 greater than 93% (World Health Organization scale ≥ 5). Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ventilation (NIV) in cohort 1; HFO, NIV, or invasive mechanical ventilation (IMV) in cohort 2; and IMV in cohort 3.<h4>Interventions</h4>Patients were randomly assigned, in a 1:1 ratio, to receive avdoralimab or placebo. 2022-01-01T00:00:00Z2022 Dec2026-05-28T01:15:19.097Z2024-10-18T22:38:10.342ZS-EPMC96744303621835410.1097/CCM.0000000000005683